Business Model Breakdown
How Perrigo Company PLC Makes Money
PRGO
Market Cap
$1.5B
Profit Margin
-43.5%
The Short Version
Perrigo Company PLC is a global consumer health company that develops, manufactures, and distributes a wide range of over-the-counter (OTC) health and wellness products, primarily for the self-care market in North America and Europe. It sells familiar products like pain relievers, cold and flu remedies, digestive health aids, and nutritional supplements, often under private labels for retailers or its own portfolio of established brands. The company generates revenue by selling these essential consumer healthcare goods through a vast network of pharmacies, grocery stores, and mass merchandisers, leveraging efficient manufacturing and supply chains to offer accessible self-care solutions.
Where the Revenue Comes From
Sale of OTC Self-Care Products (North America & Europe) (~100% of revenue)
Who buys: Retail consumers, pharmacies, mass merchandisers, grocery stores, and other retail channels.
Why It Works (Competitive Advantages)
- ✔Established brand portfolio in key self-care categories
- ✔Extensive distribution network in North America and Europe
- ✔Scale in manufacturing and supply chain
Economic Moat: Narrow (Brand Power, Efficient Scale, Intangible Assets (e.g., regulatory approvals, formulations))
What Our Analysis Says
DVR Score as of June 6, 2026
Perrigo operates in a mature and highly competitive consumer self-care market, which inherently limits its 10x growth potential. While the company reported an adjusted EPS beat in Q1 2026 ($0.43 vs $0.39 estimate), it also experienced a revenue miss and a significant net loss of $398.6 million (per prior analysis, not contradicted), indicating persistent fundamental challenges. Recent analyst adjustments, including Zacks trimming Q2 2026 EPS estimates to $0.30 and Canaccord Genuity reducing its price target, suggest ongoing headwinds. The strategic vision focuses on managing a turnaround rather than disruptive innovation or hyper-scalability. High debt levels (estimated >$5.5B) and tight liquidity (current ratio ~0.9 from Q1 2026, per training data) pose significant financial risks. Although the average analyst price target implies decent upside (~78.5%), this is far from the 10x growth required for a high score. There are no clear catalysts or expanding competitive advantages identified that would support exponential growth within the 3-5 year timeframe.